Artelo Biosciences upgraded to Buy from Hold at D. Boral Capital

D. Boral Capital upgraded Artelo Biosciences (ARTL) to Buy from Hold with a $20 price target The firm, which has adjusted its model and raised assumptions for the now completed reverse split, continues to view Artelo as an emerging biotechnology company focused on Cachexia and Chemotherapy-induced peripheral neuropathy with the lead program ART27.13, a Phase 2 asset acquired from Astra-Zenca (AZN), the analyst tells investors.